Crossmark

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Crossref DOI link: https://doi.org/10.1016/j.celrep.2019.09.032

Published Print: 2019-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cocce, Kimberly J.

Jasper, Jeff S.

Desautels, Taylor K.

Everett, Logan

Wardell, Suzanne

Westerling, Thomas

Baldi, Robert

Wright, Tricia M.

Tavares, Kendall

Yllanes, Alex

Bae, Yeeun

Blitzer, Jeremy T.

Logsdon, Craig

Rakiec, Daniel P.

Ruddy, David A.

Jiang, Tiancong

Broadwater, Gloria

Hyslop, Terry

Hall, Allison

Laine, Muriel

Phung, Linda

Greene, Geoffrey L.

Martin, Lesley-Ann

Pancholi, Sunil

Dowsett, Mitch

Detre, Simone

Marks, Jeffrey R.

Crawford, Gregory E.

Brown, Myles

Norris, John D.

Chang, Ching-yi

McDonnell, Donald P.
Funding

Funding for this research was provided by:

Susan G. Komen

National Institutes of Health
License Information

Text and Data Mining valid from 2019-10-01

Text and Data Mining valid from 2019-10-01

Version of Record valid from 2019-09-14
More Information

This article is maintained by: Elsevier

Article Title: The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Journal Title: Cell Reports

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.celrep.2019.09.032

Content Type: article

Copyright: © 2019 The Author(s).